ArchiveJune 2018

News: NICE approves ocrelizumab

NICE considers ocrelizumab to be less effective than alemtuzumab.  People with relapsing-remitting MS can only be treated with ocrelizumab if alemtuzumab is contraindicated or otherwise unsuitable. The latter is a very grey area and will be open to interpretation. My question is how does patient choice taken into account? NICE clearly does not think this is a priority; for NICE cost...

Guest post: A snapshot of current disease modifying therapies

There are many disease modifying therapies (DMTs) available for people with Relapsing MS in 2018. DMTs work to prevent MS relapses in the future, and to minimize new MRI activity over time. With many options, it can be hard to decide which therapy to start on, or which one to switch to.  Sometimes, a physician may have a preference for starting one therapy over another. However, most of the...

Stornoway research day series: The cost of MS

Dr Niall MacDougall discusses the economics behind MS and the cost to the individual, families and society. Watch Niall’s talk on our Youtube channel. And subscribe to our channel to keep up to date with our videos. This is one of the talks from the healthcare professionals day. The audience consisted of district nurses, physios, health visitors, GPs and many others that look after people...

Guest post: MSexism

Is the MS world biased against women? Another week – another news headline about how women are paid less than their male counterparts. This time it is consultants working in the NHS – and Jeremy Hunt, the UK Health Secretary, has vowed to tackle the pay gap. So what does this have to do with multiple sclerosis? A lot, I believe. By paying women consultants less than men, society is...

Real-life experience with Dimethyl Fumerate (Tecfidera)

Why is DMF so poorly tolerated?  Mult Scler Relat Disord. 2018 Jun 2;24:42-46. doi: 10.1016/j.msard.2018.05.007. [Epub ahead of print] Real-life persistence and tolerability with dimethyl fumarate. Sejbaek T1, Nybo M2, Petersen T3, Illes Z4. BACKGROUND: Dimethyl fumarate (DMF) has been registered for the treatment of relapsing-remitting multiple sclerosis (RRMS). Differences in tolerability...

Happy Anniversary Prof G

It is 25 years to the day that I arrived in London to start my PhD on body fluid biomarkers in MS.  What has changed in the last 25 years? I am still into MS body fluid biomarkers and I am fortunate to have been one of the innovators, and early adopters, of using neurofilament light chain levels in MS clinical practice. NFL is making a big difference and will almost certainly change the way...

Stornoway research day series: Self-management

MS Specialist Nurse for the Western Isles, Rachel Morrison, talks about the importance of self-management in multiple sclerosis. And she covers some top tips for managing your own condition. Watch Rachel’s talk on our Youtube channel. And subscribe to the channel to keep up to date with our new videos. The talk is part of a trip by the Barts-MS and Glasgow teams up to Stornoway, on the Isle...

Stornoway research day series: Understanding your MS symptoms

Dr Stewart Webb defines what multiple sclerosis is, and what’s going on in the body when you feel certain MS symptoms.  He distinguishes between relapses or pseudo-relapses, and the importance of treating them differently. Watch his talk on our Youtube channel. And subscribe to our channel to see other talks and videos. The talk is part of a trip by the Barts-MS and Glasgow teams up to...

Stornoway research day series: How nutrition and exercise can make a difference

Our Glasgow colleague Dr Sarah Martin discusses different diets that claim to improve MS symptoms in this talk for the people with MS and their families on the Western Isles. In the talk, Sarah outlines the difficulty of ascertaining how effective a diet is. There is a short video on the importance of Vitamin D, then Sarah shows how important exercise is for the body, especially for people with...

Stornoway research day series: What makes up the neurologist’s toolkit?

Neuro Doc Gnanapavan discusses the ways that neurologists currently diagnose and monitor MS in their patients.  She then goes on to discuss how patients can be empowered to monitor their own condition and take that knowledge to their clinician, to work together to decide the best treatment for them. This will be the future of the relationship between the clinician and the patient. Watch...

Translate

Categories

Recent Posts

Recent Comments

Archives